American Thoracic Society 2018

The American Thoracic Society 2018 International Conference will be held May 18-23, in San Diego, California. The meeting will provide respiratory medicine practitioners, scientists, clinical researchers, and related healthcare professionals research updates in pulmonary, critical care, and sleep medicine. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
May 23, 2018
Data from the Mayo Clinic suggest that smokers who have quit longer than 15 years may need to be screened for lung cancer, yet they fall outside the window recommended by the United States Preventive Services Task Force.
May 22, 2018
Researchers based at the University of Michigan compared patients admitted to the intensive care unit (ICU) in Medicaid expansion states with those in nonexpansion states, focusing on 18 specific conditions identified as severe illnesses that could be avoided through better preventive care.
May 22, 2018
From smartphones to smart rescue inhalers, researchers offered ideas to make chronic obstructive pulmonary disease care more data-driven and personalized.
May 22, 2018
Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population. 
May 22, 2018
Two scientists taking part in a session on addiction and pulmonary health outlined existing evidence about marijuana's effects on chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and cancer. But one speaker warned there are too few longitudinal studies in this area. 
May 21, 2018
Results presented at the American Thoracic Society 2018 International Conference confirm a hypothesis about the connections among pollution, inflammation, and oxidative stress. 
May 21, 2018
A session at the American Thoracic Society 2018 International Conference examined the factors that contribute to disparities and potential partnerships between doctors and lawyers on behalf of patients.
May 20, 2018
Officials with GlaxoSmithKline said COLUMBA is the first long-term study for an anti-IL5 biologic to treat severe asthma that has been reported.
May 20, 2018
Attendees at the American Thoracic Society 2018 International Conference, meeting in San Diego, California, heard details that led to FDA's recent expansion of the indication for GlaxoSmithKline's Trelegy Ellipta, including findings that the once-daily combination also provides significant mortality benefits over a dual therapy that is often the combination patients with chronic obstructive pulmonary disease (COPD) are taking when triple therapy is recommended.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.